Fragmentomics by Liqomics
Exciting News: Fragmentomics by Liqomics We are thrilled to announce that our project, Fragmentomics by LIQOMICS, has been selected as one of only 4 projects that will be supported as part of the prestigious funding program ZukunftBIO.NRW. This represents a significant milestone for us as we continue to innovate and advance the field of liquid […]
Zirkulierende Tumor-DNA (ctDNA)
Die Zukunft der Krebsdiagnostik: Zirkulierende Tumor-DNA (ctDNA) (Teil II) In unserem letzten Artikel haben wir die Grundlagen der zirkulierenden zellfreien DNA (cfDNA), ihre Freisetzungs- und Ausscheidungsmechanismen sowie ihre zentrale Rolle in der Krebsdiagnostik vorgestellt. Da Sie nun mit den grundlegenden Konzepten von cfDNA vertraut sind, möchten wir in diesem Folgeartikel tiefer in ihre biologische Bedeutung […]
LymphoVista HL assay at the ASH 2024, MRD in Hodgkin Lymphoma
LymphoVista HL Assay results presented at ASH 2024 Annual Meeting Liqomics, a leading innovator in cancer diagnostics, is thrilled to announce the presentation of data on the LymphoVista HL assay at the 2024 Annual Meeting of the American Society of Hematology (ASH) in San Diego. This cutting-edge circulating tumor DNA (ctDNA) assay is tailored for […]
Krebsdiagnostik durch ctDNA
Die Zukunft der Krebsdiagnostik: Zirkulierende Tumor-DNA (ctDNA) Die jüngsten Fortschritte in der Krebsforschung haben unser Verständnis der komplexen Tumorbiologie deutlich erweitert. Besonders vielversprechend ist die Untersuchung zirkulierender Tumor-DNA (ctDNA) – winziger, zellfreier DNA-Fragmente, die von Krebszellen in die Blutbahn abgegeben werden. Der Nachweis und die Analyse dieser Fragmente ermöglichen einen innovativen Ansatz für die Krebsdiagnose […]
Cancer diagnostics with ctDNA
Unlocking the Future of Cancer Diagnostics with Circulating Tumor DNA (ctDNA) Advances in cancer research have brought us closer to understanding the complex biology of tumors. One particularly promising area is the study of circulating tumor DNA (ctDNA)—tiny cell-free DNA fragments shed by cancer cells into the bloodstream. Detecting and analyzing these fragments represents a […]
Minimal residual disease (MRD) in liquid biopsy
Minimal Residual Disease (MRD) in liquid biopsy (Part II) In our previous article, we explored the importance of minimal residual disease (MRD) in cancer treatment, highlighting its role in predicting relapse and guiding personalized care. In this follow-up, we will delve into the methods used to measure MRD, the significance of MRD positivity and negativity, […]
Minimal Residual Disease (MRD) in cancer
Minimal Residual Disease (MRD) in cancer (Part I) Introduction In the field of cancer treatment, early and accurate diagnosis is only part of the challenge. Ensuring that a patient remains cancer-free after initial treatment is equally critical, as cancer has a habit of returning if any malignant cells remain. This is where minimal or measurable […]
Exciting Updates for the Hematology and Oncology Community
Exciting Updates for the Hematology and Oncology Community – Minimal Residual Disease in Hodgkin Lymphoma We’re thrilled that next week, from October 26-28, 2024, the highly anticipated 13th International Symposium on Hodgkin Lymphoma (ISHL 13) will take place in Cologne. This world-renowned event brings together leading experts, researchers, and clinicians in the field of hematology […]
Understanding Minimal Residual Disease (MRD)
Understanding Minimal Residual Disease (MRD): A Guide to Some Helpful Calculations when Analyzing ctDNA Minimal residual disease (MRD) detection through circulating tumor DNA (ctDNA) is gaining attention as a precise tool to measure residual cancer during and after treatment. Have you ever thought about what the MRD values mean? Let’s break down how one could […]
Lookout for collaborators
Minimal residual disease assessment We are always on the lookout for collaborators. Academic research, start-up or pharmaceutical industry. If you are excited about blood-based cancer genomics or highly sensitive minimal residual disease assessment across cancers we should start a conversation. Get in contact with us and let us explore how we can team up.